Portfolio

Engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera's single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a unique combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence, and laboratory automation.

Biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates. With an initial focus on immunology, ACELYRIN is targeting both early-stage innovation as well as clinical-stage programs where it can leverage its expertise to rapidly advance medicines to patients.

Acutus is working to develop a novel electro-anatomical mapping catheter for atrial fibrillation ablation procedures. The Acutus system integrates ultrasound technology and a proprietary dipole density mapping technology to generate a three dimensional image of the left atrium over which the electric activity of the chamber can be precisely displayed in real time.

A commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, and central nervous system diseases.

Clinical stage company developing first-in-class ADCs for the treatment of cancers. Lead program (ADCE-T02) targets tissue factor with an antibody designed for minimized interference with the coagulation pathway, reducing the risk of bleeding. ADCE-T02 uses a clinically validated linker-payload platform designed for improved bystander activity and linker stability

Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. The company’s genome-wide methylation analysis technology has the unique ability to distinguish the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially target those informative regions for sequencing.

Adicet Bio, Inc., is developing a novel universal immune-cell therapy platform for cancer and other disease indications and novel immunotherapies directed to disease-specific targets derived from the intracellular proteome.

Advanced Enzymes is a leading enzyme company in India with a portfolio of over 400 unique enzyme products.

Developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs

Aerin Medical is developing non-invasive procedures for the treatment of chronic nasal airway conditions. The company’s FDA-cleared products, the VivAer® Stylus for nasal airway obstruction and the RhinAer® Stylus for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with a nonsurgical procedure under local anesthetic in their offices.

AIMS (Asian Institute of Medical Sciences) Hospital is one of the leading multi-specialty hospital chains in North India with a growing presence in East India. The Company has a network of 6 hospitals across Tier 2 and 3 cities.

AK Medical is the leader in joint replacement products and solutions in China. The company has a wide range of orthopedic products, covering over 2,000 hospitals through more than 500 distributors. AK medical is also the pioneer of applying 3D printing technology in orthopedics products.

Alentis is a clinical stage biotech company developing first-in-class ADCs and antibodies targeting Claudin-1 for the treatment of solid tumors and fibrosis

Aliada is developing a platform to improve drug delivery to the brain for multiple modalities including, monoclonal antibodies, enzymes, and oligonucleotides

Alpheus™ Medical, Inc., is developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers. The company's lead product utilizes a novel, non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).

Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. The company is led by seasoned R&D leaders with a history of developing marketed oncology small molecule drugs.

Amolyt Pharma developing two therapeutic peptides for rare endocrine and metabolic diseases AZP-3601, a conformation specific PTH analogue, an analog of IGFBP2, a key regulator of fat, glucose and bone metabolism for glucose control in rare genetic Lipodystrophies and insulin receptor-opathies.

AnchorDx is a leading liquid biopsy company to develop cancer early detection products and to provide clinical laboratory testing services. The company has developed a broad pipeline of products in cancer early detection and recurrence monitoring, which focuses on multiple major cancer types using blood and urine-based NGS and qPCR assays.

A Chinese biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases globally.

Biotechnology company advancing novel therapies to address the needs of patients with immunological and inflammatory disorders. Apogee is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways

Arcatron is a consumer medical company offering mobility assist devices like wheelchairs for patients with limited mobility and orthopedic body supports for pain relief and comfort enhancement. Arcatron follows an online-first marketing approach and sells its products across its own D2C website, online marketplaces, and offline channels.

ArCHitect Therapeutics is developing oral therapies by targeting disease drivers that have been difficult-to-drug with existing chemistry. Its approach transforms dormant carbon-hydrogen (C-H) bonds – the most common bonds in small molecules – into powerful building blocks of novel drug architectures.

ArriVent is a clinical-stage drug development platform company focusing on identifying, licensing and unlocking the global value of top biotech innovations from China into the U.S. The company has in-licensed multiple assets of various modalities including small molecules, large molecules, ADCs, etc.

ARS is developing treatments for patients and parents affected by severe allergic reactions that are safe and effective, needle-free, easy to carry, and simple to administer

Asceneuron is a clinical stage biotech company developing orally bioavailable therapeutics targeting tau protein aggregation for the treatment of neurodegenerative diseases.

Aspen Neuroscience is focused on developing induced pluripotent stem cells to treat neurological conditions.

Clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases

Developing the next generation of oncology therapies for patients

Developing mRNA-encoded genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases in a redosable format

Aviceda is a clinical-stage company harnessing immune cells’ natural checkpoints for the treatment of diseases characterized by chronic, non-resolving inflammation. Its lead asset is an intravitreal, synthesized sialic acid-coated nanoparticle in Phase 2b/3 development for geographic atrophy

A regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL System technology platform, approved by the Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects and for repigmentation of stable depigmented vitiligo lesions, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin cells.

Avitide develops customized biopharmaceutical affinity purification products. The Avitide platform reduces bioprocess development timelines, program risk, and cost of manufacture by providing turnkey, cost-effective, highly specific affinity purification solutions. Industry-leading affinity resin discovery timelines integrate seamlessly into process development cycles, providing improved line-ofsight, platform operations and equipment, and predictable scalability.

Azura Ophthalmics is a clinical-stage biotechnology company headquartered in Tel Aviv-Yafo, Israel. Azura Ophthalmics is developing an innovative portfolio of compounds – in combination with a novel drug delivery platform – to advance treatments for lid margin diseases such as Meibomian gland dysfunction (MGD), the leading cause of dry eye disease.

A leading china specialty pharma for developing innovative biologics for treating cancers

Star Sport Medicine is the leader in sports medicine in China, which provides surgical products and clinical solutions in sports medicine, including active surgical equipment and consumables in areas of knee, shoulder, ankle, elbow, hip and small joints

binx io is a first-of-its-kind, highly sensitive and specific, point-of-care (POC) diagnostic testing platform and is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the world’s first sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)– the two most tested-for STIs globally.

Clinical-stage company developing an oral small molecule apelin receptor agonist for obesity, with a focus on improving the quality of weight loss through muscle preservation.

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

A China based clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative medicines for cancer and other life-threatening diseases with high unmet medical needs

BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D. and biotech veteran, Y. Peter Li, Ph.D., M.B.A.

BMTfemme is commercializing an AI-powered portable colposcope, enabling primary care providers to perform specialist-level visual diagnosis of gynecological conditions.

Advanced laser-based intravascular lithotripsy (IVL) platform that delivers consistent acoustic output to treat calcification across variety of vessel beds.

Bonovo is a leading provider of orthopedic products to the Chinese healthcare market. Bonovo has over 15 years of experience manufacturing and distributing orthopedic products throughout China. Bonovo's unique relationships with leading clinicians and hospitals makes Bonovo an ideal partner for access to the Chinese orthopedic market.

CalciMedica’s proprietary technology targets the inhibition of CRAC channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies.

Candid Therapeutics is an innovative biotechnology company dedicated to advancing T cell engagers for the treatment of immunological diseases. Established in 2024 and headquartered in San Diego, CA, Candid is driven by a team of repeatedly successful entrepreneurs with deep expertise and strong execution abilities. Supported by a distinguished syndicate of leading healthcare investors, Candid is committed to discovering and developing cutting-edge therapeutic programs that address significant unmet medical needs in immunology.

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. The company is combining the power of cell therapy with the precision of genetic medicines to develop new treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. The Company was co-founded by pioneers in the field of CAR-based immunotherapy, nucleic acid drug delivery, tLNPs, and regenerative medicine, including experienced industry leaders, as well as academic faculty members from the University of Pennsylvania. Capstan has a bicoastal presence with operations in San Diego, CA and Philadelphia, PA.

A leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease.

Carrot Fertility is a global fertility benefits provider for employers, built to support employees as they navigate the fertility journey by offering financial benefit and high-touch support. Companies use Carrot to customize a fertility benefit that provides employees financial, medical, and emotional support as they pursue parenthood.

Cellipont Bioservices is a privately held cell therapy CDMO operating in The Woodlands, TX with more than 15 years of experience in the development and manufacturing of cell therapies, ranging from small to large-scale batches. Cellipont has deep technical expertise and has been recognized by customers and partners for its ability to productively grow challenging cell types.

CHARM Therapeutics is applying its end-to-end 3D deep learning protein-ligand co-folding technology, DragonFold, to develop small molecule therapeutics against previously hard-to-drug targets in cancer and other therapeutic areas

Chemomab is developing novel chemokine blocking therapies for inflammatory and fibrotic disorders

Compass Therapeutics is seeking to cure various cancer types through combination therapy by comprehensively drugging the tumor-immune synapse with human antibodies against over 50 cell surface and soluble targets

Congruence Therapeutics is a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. Using structural bioinformatics, computational chemistry, and machine learning, the Company is deploying an in-silico platform that enables the design of new pharmacological stabilizers, a validated class of small molecules, at an unprecedented speed and scale.

Clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate cancer

Corteria is a Sanofi spin out developing long acting corticotrophin release factor type 2 receptor (CRF2) agonists to overcome the limitations of short half-life urocortin analogs for use in heart failure.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. Using both small molecule and monoclonal antibody approaches, Corvus brings together scientists who played key roles in the development of Rituxan, Imbruvica, and Zelboraf to advance new immuno-oncology therapeutics.

Credit Pharma is a Central Nervous System focused leading pharmaceutical company in China with integrated R&D, manufacturing, and sales & marketing capabilities.

Crinetics Pharmaceuticals is a clinical-stage biotechnology company focusing on treatments for rare endocrine disorders and endocrine-related cancers. The company is currently conducting a Phase 3 trial with its oral somatostatin agonist, Paltusotine, for the treatment of acromegaly, an orphan disease affecting more than 24,000 people in the United States. The company is also developing other oral somatostatin agonists for neuroendocrine tumors, hyperinsulinism, and chronic pain, as well as an oral small molecule for Cushing’s disease.

Cullinan Therapeutics is built to develop a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. The company's portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class.

Curevo is a privately held, clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing vaccines with improved tolerability and accessibility. Curevo’s lead product is amezosvatein, an adjuvanted sub-unit vaccine to prevent shingles.

Cyrus Biotechnology is a privately-held biotechnology software company offering protein modeling and design capabilities to the biopharmaceutical, chemical, consumer products and synthetic biology industries. The company was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of biologics and small molecules.

CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. CytomX’s lead asset, CX-2051, is currently in clinical development for advanced colorectal cancer.

Dami & Xiaomi is a healthcare services provider for children suffering from Autism Spectrum Disorder (ASD) or other developmental disabilities. Services such as ABA, speech therapy, and others are delivered to the patients through treatment centers

Dehan Dental is a leading dental chain in China, with Wuhan as its headquarters, covering several surrounding provinces, providing international orthodontics, dental implants and other key dental services.

Delfi Diagnostics is developing a new class of high performance, affordable liquid biopsy tests for early cancer detection. Leveraging recent advances in cancer biology and machine learning, Delfi’s technology can achieve high performance from low-cost, widely available sequencing technology.

Focusing on improving functions & performance and enhancing medication safety & efficacy, DIH aspires to be a premier technology & application platform leader in Rehab & Sports Medicine (RSM) and Intelligent Medication & Supply (IMS) businesses, enabled by passionate teams working around the globe.

Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic disorders. Disc Medicine is building a unique portfolio of innovative, first-in-class therapeutic candidates based on fundamental pathways of red blood cell biology.

Leading Chinese company in general laboratory devices & instruments with R&D, manufacturing, and sales & marketing capabilities.

EC Healthcare is Hong Kong's largest non-hospital medical service provider focusing on preventive and precision medicine to build the leading one-stop healthcare ECOSYSTEM with a mission to bring Health, Beauty, and Happiness to more People. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN, which has ranked first in Hong Kong by sales for years and other diversified and multi-dimensional medical services.

Eddingpharm is a leading pharmaceuticals marketing company in the fast growing China market. It focuses on in-licensing, marketing and distributing hospital pharmaceutical products.\r\n\r\n With over 20 offices and 400 professional sales representatives, Eddingpharm is a partner of choice for many multi-national pharmaceutical companies.

Edgewise Therapeutics builds on our extensive experience in drug development and skeletal muscle research. Edgewise has built a custom discovery workshop for the discovery and optimization of novel therapeutics for a broad set of indications where skeletal muscle function is compromised.

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and depletes pathological immune cells.

EnLiven Therapeutics is a targeted oncology company developing small molecule kinase inhibitors. Enliven’s approach combines clinically validated biological targets and industry-leading chemistry to design best-in-class and first-in class therapies to address unmet needs in cancer.

Entero is one of the largest pharmaceutical and medical device distribution companies in India. It has an extensive customer base of retail pharmacies and hospitals. Entero distributes products for most of the leading companies in the country through its pan-India network of state-of-the-art warehouses and technology infrastructure.

ENYO Pharma is a clinical stage biotech with a unique drug discovery engine inspired by viruses. The company is currently entering Phase 2 with its lead compound Vonafexor in Alport Syndrome.

Epigenic Therapeutics is a clinical-stage biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for viral, cardiometabolic, ophthalmology and neurodegenerative diseases.

Ethris is paving a new path from genes to therapeutic proteins using its proprietary messenger RNA technology platform, which enables the discovery, design and development of transcript therapies that drive the production of therapeutic proteins within patients’ cells and tissues. The company’s lead program ETH42 is in preclinical development for treatment of a rare pulmonary disease, primary ciliary dyskinesia.

Eurolife Healthcare manufactures and distributes a portfolio of healthcare formulations, intravenous infusions, ophthalmics, and sterilized water for injections. They have manufacturing facilities in India and Hungary (EU-GMP approved).

Evox Therapeutics is a biotechnology company focused on improving the natural delivery capabilities of exosomes. Evox has developed a proprietary technology platform, DeliverEX, to enable it to modify exosomes, to load drugs into exosomes, and to target the delivery of these exosomes to organs of interest.

Evozyne creates novel protein systems that enable a healthier world.

A personalized medicine diagnostics company assessing the activity of mutations and combination of mutations and their response to targeted drugs

Forsight Vision 6 is developing an Accommodating Interocular Lens (AIOL) which aims to enable pristine vision across all distances post cataract surgery. The approach is differentiated, placing the lens over rather than in the capsular bag, thereby avoiding the stiffening which hinders accommodation. Founders and leadership are composed of world class ophthalmology veterans.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate for potentially broad autoimmune and autoimmune-related indications.

Forward Therapeutics is a biopharmaceutical company dedicated to transforming the treatment of chronic inflammatory disorders.

Leading gene therapy player developing high quality but affordably priced rAAV based therapeutics for the China market. The company currently has three programs in clinical trials, including FT-001 for LCA2, FT-002 for XLRP, and FT-003 for wet AMD and DME. It also has multiple preclinical programs for metabolic, cardiovascular, and CNS indications.

FUSmobile is developing a handheld focused ultrasound device, addressing pain non-invasively, with initial focus on back pain.

At FutuRx, Johnson & Johnson Innovation - JJDC, Takeda Ventures Inc. and OrbiMed Israel Partners teamed with the Office of the Chief Scientist of the Ministry of Economy in a national initiative to transform breakthrough discoveries into novel medicines. FutuRx envisions its role as a catalyst for drug development by bridging the gap between concept and proof-of-concept through its dedicated system and unique structure

Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases. As the industry’s first off-the-shelf offering, Garuda’s technology has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells.

Gaush Medical is one of the largest ophthalmic device companies in China with both distribution and proprietary product business.

Gennao Bio is a genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio’s proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics.

GliXogen Therapeutics is developing novel inhibitors of the transcription factor Gli1 to enhance remyelination in demyelination indication such as multiple sclerosis. Inhibition of Gli1 results in robust differentiation of neural stem cells into remyelination oligodendrocytes which migrate to white matter lesion sites and generate functional myelin. GliXogen have identified highly potent, orally bioavailable and brain penetrant molecules which have shown impressive in vivo efficacy in several demyelinating models and are now in lead optimization stages.

Leading connected clinical services provider for primary care clinics in China with a cloud-based platform supporting the delivery of nurse practitioner and specialized treatment services, clinical lab testing services, telemedicine, and other online services

Market-leading, integrated, full service global clinical CRO with APAC & US centric operations and differentiating specialties in clinical development and data analytics.

Helicore Biopharma, Inc., is a clinical-stage multi-product biopharmaceutical company focused on the discovery and development of novel weight-loss therapeutics. Helicore’s proprietary platform leverages monoclonal antibodies that bind circulating GIP ligand, designed to improve the efficacy, dosing, and tolerability of anti-obesity therapies.

The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs.

A mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need. iECURE’s approach focuses on the in vivo insertion of healthy copies of disease-causing genes, with an initial focus in liver disorders.

Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.

ImmPACT-Bio is developing a novel Chimeric Antigen Receptor T-cell (CAR-T) strategy that uniquely differentiates cancerous from non-cancerous tissues, and specifically addresses a common mechanism, loss of allelic heterozygosity (LOH), for tumor immune-escape. Our approach will expand the target repitiore for CAR T therapies in solid tumors. The company was founded at the FutuRx incubator based on the research of Prof. Gideon Gross, an early leader in immunogene therapy who invented the first CAR in Zelig Eshhar’s lab at the Weizmann Institute.

Innvolution focuses on interventional cardiology with a comprehensive portfolio of products including imaging equipment and consumables. It is the largest indigenous manufacturer and supplier of Catheterization Laboratories (Cath Labs) in India. The company has a strong pan-India distribution network with multiple touchpoints across hospitals and interventional cardiologists.

Insilico Medicine is developing next-generation artificial intelligence to cost down, accelerate, and increase the success rates in drug discovery and development. The company is constantly making breakthroughs in early stage R&D, launching software products, and advancing its own internal pipeline of small molecule therapeutics.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan.

InspireMD is a commercial-stage medical device company developing novel carotid stent technologies with integrated embolic prevention systems (EPS) to deliver neurovascular protection and stroke prevention.

InventisBio is dedicated to deliver best- and first-in-class drug for cancer and metabolic disease to address large unmet medical need

Invivyd is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. The company’s candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect.

Janux Therapeutics is developing novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets and can be applied to immunotherapies that target all three stages of an anti-tumor immune response.

Jinxin Fuxing Eldercare is one of the largest eldercare services companies in China. The company’s “three-in-one” care model focuses on the combination of high-quality clinical and regular eldercare services across facilities, community, and home care settings.

Kapiva is a leading health and wellness-focused consumer company marketing natural and Ayurveda products to the 20-45-year age group. The Company offers products for men’s health, skin and hair, weight management, lifestyle diseases, and daily wellness. Kapiva has an omnichannel distribution with a digital-first approach and is emerging as a leader amongst the direct-to-consumer natural and Ayurveda companies in India.

Kartos Therapeutics is a clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta, or TGF-beta, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone.

Kumquat’s mission is to develop innovative therapies to bring about sustainable and life-changing benefits to cancer patients.

Laekna Therapeutics is a biotech company dedicated to the discovery and development of novel therapeutics for oncology and metabolic diseases

Lattice MedTech is a OrbiMed incubated healthcare platform providing end-to-end distribution, market access and expansion solutions in medical device segment. Lattice MedTech offers solutions across medical consumables, implants, and capital equipment, driving local distribution and full-service market expansion.

Laxmi Dental is a leading dental products and lab services company offering crowns, bridges, aligners, and pediatric products for domestic and export markets. The Company has a global reach and caters to a large network of dentists in India, the USA, and Europe.

Developing novel therapeutics for patients with major disorders of the central nervous system

LifeCell is an established and trusted consumer healthcare services brand focused on maternal and child health. The Company operates India’s largest cord blood bank and is an emerging leader in the fast-growing reproductive diagnostics segment. The Company also offers placental tissue-based products that support the healing of chronic wounds.

Lomond Therapeutics is a small molecule oncology drug discovery company committed to defeating and curing cancer.

Medical device company developing self-expanding percutaneous mechanical circulatory support pumps intended to provide minimally-invasive support to the native heart during acute episodes of dysfunction.

Marksans Pharma Limited is engaged in manufacturing, research and marketing of generic pharmaceutical formulations globally. Key focus areas are OTC and prescription (Rx) drugs across various therapeutic categories such as Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic.

MBX Biosciences is a biotechnology company creating therapies for rare endocrine diseases. MBX is strengthened by world-class proprietary peptide drug discovery capabilities.

MDClone was founded to address one of the most critical bottle necks in the healthcare market by creating synthetic medical records, based on real data with interactive anonymization. Allowing for greater utilization of existing medical data in a manner that does not infringe on patients' privacy

Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases.

Memebox has a diverse portfolio of clean beauty and hypoallergenic brands including I Dew Care, Kaja, Nooni, Pony Effect, I'm Meme.

MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates.

Mirador Therapeutics envisions a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and better development accuracy.

NeRRe Therapeutics is a clinical stage company developing a portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity. The company was formed in December 2012 and is focused on the development of a portfolio of NK receptor antagonists acquired from GlaxoSmithKline, which have therapeutic potential in a broad range of indications.

A commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need.

Neurogastrx is a biopharmaceutical company focused on discovering and developing transformative therapies for gastrointestinal disorders affecting the enteric nervous system.

NeuroPace is a commercial-stage medical device company that markets the Responsive Neurostimulation (RNS) System for medically refractory epilepsy with 1 or 2 epileptogenic foci. The RNS System continually monitors brainwaves for unusual activity and is able to respond instantly with corrective stimulation, thereby reducing seizure frequency; it is the first and only closed-loop responsive neurostimulation system.

Leading transcatheter heart valve medical device company in China with broad product pipeline covering all the transcatheter procedures of mitral valve replacement, mitral valve repair, and aortic valve replacement

NextCure, launched in 2015, is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products

Noctrix Health is a pioneer in developing the next-generation of wearable therapeutics. Backed by scientific evidence and clinical data, it aims to make prescription-grade medical devices accessible so physicians and patients have more choices beyond the pill.

Hunan Norchem Pharmaceutical is a leading steroid drug intermediates/API provider, and synthetic biology industrialization platform company in China. Over the last decade, the company gradually became one of the largest steroid intermediates providers in the world and has built a large-scale R&D and biomanufacturing platform.

Nucleix develops, manufactures and markets revolutionary non-invasive molecular cancer diagnostic tests. Nucleix's highly sensitive and specific tests are based on identification of subtle changes in methylation patterns

Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next generation immunomodulators and oncology medicines. Comprised of an expert team of drug hunters and executives, Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines

OmniGuide, Inc. is a patient safety-focused medical technology innovator, providing a portfolio of advanced energy surgical tools to benefit clinicians and their patients alike. The company’s technologies deliver energy in a precise and electrically silent manner, resulting in the preservation of healthy tissue. OmniGuide Surgical, a leader in flexible fiber CO2 laser technology, offers a range of products designed to enhance surgical accuracy, access, and control for minimally invasive surgery, laparoscopy, and robotic-assisted surgery. Domain Surgical, by OmniGuide, Inc., provides a patented ferromagnetic technology designed to provide safety and predictability in selected surgical procedures that require cutting, coagulating, and sealing of tissue. LISA Laser Products GmbH, a leader in holmium and thulium laser technology, offers a wide range of products focused on improving clinical and patient outcomes in otolaryngology, neuro, and urological surgical procedures.

Dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, including CUSP06, a CDH6 ADC.

Ottimo Pharma is a private biotechnology company focused on the development of cancer therapies for solid tumors. The company’s lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration, and license agreement with the University of Pennsylvania.

Committed to the development of multiple advanced therapeutics that address unmet needs in the management of end-stage kidney disease

Perfuse Therapeutics is a clinical-stage biotechnology company pursuing a novel mechanism to improve retinal perfusion in the context of various retinal diseases, starting with glaucoma.

PIC Therapeutics is focused on fundamentally changing how we treat cancer by discovering and developing first-in mechanism, first-in-class small molecule therapeutics that modulate protein translation.

PMV Pharma is developing first-in-class wildtype and mutant allele-specific p53 modulators for the treatment of cancer.  Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Prelude Therapeutics is a biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer.

Clinical-stage biotechnology company developing a pipeline of multiple antibody-drug conjugate therapeutics targeting solid tumors and hematological malignancies. The Company’s lead ADC program, rinatabart sesutecan, is targeting FRa

Prothelia is a preclinical-stage biopharmaceutical company focused on the development of novel therapeutic proteins to treat rare muscle diseases with extremely high unmet need. Prothelia is initially focusing on patients with LAMA2 deficient congenital MD.

A leading artery denervation platform company in China developing novel therapies in pulmonary hypertension, heart failure, and hypertension

Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.

A global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro-orphan diseases, and oncology.

Committed to realizing the potential of gene therapy to provide safe, long-lasting treatments for a wide range of diseases. Rampart’s versatile approach is driven by proprietary development and delivery platforms, which together create optimized therapeutics in a redosable, non-viral format.

RAPT is a clinical stage biotech advancing a half-life extended anti-immunoglobulin E (IgE) monoclonal antibody for food allergy

RayThera is a small molecule drug discovery company focused on developing safer, more effective therapies for immunological diseases.

ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases. The Company’s diverse pipeline includes lead programs for cystic fibrosis caused by nonsense mutations, and primary ciliary dyskinesia. ReCode has developed a non-viral delivery therapeutic platform that enables it to precisely deliver its medicines safely and effectively.

Leading POCT company in China offering both reagents and instruments covering a broad range of cardiac and hematology tests

Renasant Bio is pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.

Repare is a clinical-stage precision oncology company using its CRISPR-based SNIPRx® platform to develop and target specific vulnerabilities of tumor cells

scPharmaceuticals is developing a portfolio of pharmaceutical products for subcutaneous delivery. The company is focused on facilitating the subcutaneous delivery of drugs that currently require intravenous or intramuscular injections via a proprietary patch pump technology.

Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine.

Sikka Software develops cloud platform technologies to enhance practice economics, improve the quality of care and service experience for patients, and provide suppliers with more effective ways to reach clinicians and patients. Sikka focuses on the non-physician, non-hospital healthcare segments, which include dentistry, veterinary, audiology, optometry, and other adjacent markets, both in the US and internationally

Sionna Therapeutics is a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF

Sirius Therapeutics is a clinical-stage, leading developer of RNAi therapeutics for the management of chronic diseases. Sirius was founded in 2021 with a world-class leadership team and investors. Leveraging the proprietary RNAi technology, the company offers a portfolio of solutions for patients to change the future of cardiovascular disease.

Developer of anti-inflammatory medicines for the treatment of neurodegenerative diseases and inflammatory diseases.

Clinical-stage company developing isoform-selective inhibitors of the voltage gated sodium channel for the treatments of pain and other peripheral hypersensitivity disorders.

A leading neuromodulation company providing a full solution of pain management devices and devices for other disease areas.

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess. Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular corticosteroids in key tissues.

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Stairmed is the leader in developing proprietary technology platforms and products in invasive brain-computer interface (BCI). The company focuses on developing products for both neuroscience research and clinical applications targeting motor function impairments and neurodegenerative diseases.

Biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients who lack effective treatment options. Star consists of a family of companies, each focused on a specific area of biology with first-in-class therapies that each target multiple diseases.

Suraksha is the leading diagnostics company in Eastern India offering pathology and radiology services. The Company has a strong brand in the region and offers a comprehensive suite of diagnostic tests. Suraksha’s central lab features Eastern India’s largest fully automated robotic track and is accredited by College of American Pathologists (CAP) and National Accreditation Board for Testing and Calibration Laboratories (NABL).

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform, and is rapidly expanding the state-of-the-art high-performance computing clusters and wet labs to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community.

TELA Bio (Nasdaq: TELA) is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA’s products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA's portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.

Tendfo is a clinical stage medtech company focusing on developing interventional
devices for venous thromboembolism diseases (VTE), including pulmonary
embolism (PE), deep vein thrombosis (DVT), and other diseases sharing the same
vascular path

Tergus Pharma is an end-to-end service provider for topical pharmaceutical products supporting early phase research and formulation, drug development, testing, and both clinical and commercial manufacturing.

Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets.

Terremoto Biosciences is advancing its lysine-based covalency platform to expand the covalent drug alphabet and develop small molecule medicines for a range of highly complex diseases, including cancer

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. The lead product candidate, THB001, is the first highly selective, oral small-molecule KIT inhibitor to enter clinical development.

Used in over 3,000 facilities, TigerConnect has established itself as the leader in secure messaging for healthcare. From large hospital networks to small private practices, healthcare organizations use TigerConnect as their preferred method of secure communication to comply with HIPAA, HITECH and other industry standards.

Clinical-stage biotech advancing three potential best-in-class assets, including a cap-dependent endonuclease inhibitor for influenza, protease inhibitor for COVID19, and CDK4/6 inhibitor for LGEEC

Treeline Biosciences is a biotechnology company prioritizing molecular targets in oncology that are validated but difficult to drug. Treeline’s mission is to develop a pipeline using its four pillars of drug discovery: mechanistic biology, medicinal chemistry, computational science, and structural biology and protein science.

TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors.

Pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of Immunology & Inflammation disorders, including Atopic Dermatitis.

Turnstone Biologics is developing a first-in-class, systemically-administered oncolytic viral immunotherapy that combines a bioselected and engineered Maraba virus to directly lyse tumors with a potent vaccine that drives tumor-antigen specific T-cell responses of unprecedented magnitude

TytoCare provides the missing link in telehealth - a digital examination tool and platform that connects patients at home to clinicians, to better inform their diagnoses. TytoCare expands the range of conditions that can be reliably diagnosed via telehealth by capturing comprehensive physical exam data at home and delivering it to a remote physician.

Upper Biotech is a leading POCT diagnostics company in China. The Company currently offers products in the areas of infectious diseases, women's health, cardiology, and diabetes. The company has a customer base of over 2,000 hospitals in China.

Upstream Bio is a biotechnology company focused on developing therapeutics that address allergic and inflammatory diseases through upstream targeting

Uquifa is a small molecule CDMO providing development and manufacturing services to originator and generic customers for chemical intermediates and finished Active Pharmaceutical Ingredients (APIs). It has R&D and cGMP manufacturing facilities in Europe, North America, and India.

A specialty vaccine company providing prevention against diseases with major unmet medical needs. The Company has a growing commercial business with two successful vaccines for travelers. Our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today and the only single-shot chikungunya vaccine candidate.

Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases. The company’s lead program is focused on developing small-molecule activators of glucocerebrosidase (GCase) that have the potential to treat Parkinson’s disease patients as well as those with Gaucher disease.

Velsera is the precision engine company. Velsera connects healthcare and life sciences to reveal the true promise of precision medicine - a continuous flow of knowledge among researchers, scientists and clinicians around the world, creating insights that radically improve human health. Velsera comprises three global, industry leading organizations in the healthcare and life science industries: Pierian, Seven Bridges, and UgenTec.

Verastem is a late stage development biopharma advancing novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK and FAK inhibition

Verdiva is a clinical-stage company committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications.

A dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, Verrica’s lead product, YCANTH™ (cantharidin) (formerly known as VP-102), became the first treatment approved by the FDA to treat pediatric and adult patients with molluscum contagiosum, a highly contagious viral skin infection affecting approximately six million people in the United States, primarily children

Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the Angiotensin II Type 2 Receptor (AT2R) has a central role in stopping and reversing disease pathology.

vVARDIS is a developer and manufacturer of unique dental products under the Curodont brand, including their innovative drill-free treatment for early tooth decay.

Whale Imaging focuses on the R&D, manufacturing, and marketing of high-tech medical imaging devices which utilizes the company's unique core competencies that combine lowest cost manufacture with high level management experience. We combine low-cost R&D and manufacturing with a highly-skilled and experienced management and workforce to produce high quality and optimal value for our customers, above average returns for our stakeholders, and opportunity for our employees. Our aim is to be the leader in producing affordable world-class medical imaging systems to our global customers by leveraging our proven proprietary disruptive technology, management expertise, and low-cost manufacturing capabilities in China.

Clinical stage company developing a long-acting anti-TSLP monoclonal antibody for the treatment of asthma and COPD with the potential for every 6-month dosing. Windward is also building a discovery pipeline of long-acting, bispecific antibodies for immunology indications.

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant seeks to leverage its resources to successfully compete in global neurological and orthopedic surgery markets.

Chenxing Pharmatech is a CRO company based in Beijing. Its business scope includes CMC and manufacturing process development of small molecule APIs, formulation, bioequivalence studies and clinical trials.

Zentera is a Shanghai based clinical stage biopharmaceutical company focused on developing cancer therapies. Zentera has licensed multiple clinical stage programs and R&D technologies from Zentalis (NASDAQ: ZNTL), and is also development its proprietary technologies for oncology patients in China and global

Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company has research teams operating in Shanghai and Suzhou. In response to a large number of unmet clinical needs, the company is capitalizing on its DMPK expertise, to develop a pipeline of “best-in-class” and “first-in-class” drugs. The company is founded by veterans in industry with years of experiences from MNC. Currently multiple proprietary in-house discovered programs are approaching clinical stage.

Leading neurology and vascular intervention medical device company in China, with the most comprehensive range of pipeline products covering all the key consumables used in neurovascular and peripheral vascular interventional procedures